Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate · participants with Helicobacter pylori infection
The intervention showed no clear difference in adverse events rate (high certainty).
1 finding from 1 review
Intervention not reported
Discontinuation for adverse events · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load
The intervention showed no clear difference in discontinuation for adverse events (moderate certainty).
1 finding from 1 review